Building on the favorable findings from TROPION-Lung02, the TROPION-Lung07 study, which is currently ongoing with 1170 patients enrolled, was initiated as a phase III clinical trial to evaluate Dato-DXd combination therapy as a first-line treatment option for patients with non-squamous a/mNSCLC who lack actionable genomic alterations and have low PD-L1 expression (tumor proportion score [TPS] < 50%). The gene discussed is CD274; the disease is neoplasm.